Conference
LBA9_PR genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)
Authors
Fizazi K; Hotte SJ; Saad F; Alekseev B; Matveev VB; Flechon A; Gravis G; Joly F; Chi KN; Malik Z
Volume
27
Publisher
Elsevier
Publication Date
October 2016
DOI
10.1093/annonc/mdw435.20
Conference proceedings
Annals of Oncology
ISSN
0923-7534